HOME >> BIOLOGY >> NEWS
APS President-Elect Carey urges 6.7 percent increase for biomedical research

WASHINGTON -- (March 27, 2007) Hannah V. Carey, Ph.D., president-elect of The American Physiological Society (APS; www.the-aps.org) and a professor at the University of Wisconsin School of Veterinary Medicine, today urged Congress to increase funding for the National Institutes of Health (NIH), the nations largest funding source for biomedical research. A 6.7 percent increase in funding for the next fiscal year will help solve pressing health problems such as obesity, heart disease, diabetes and cancer, Carey told the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, and Education.

Carey expressed appreciation on behalf of the scientific community for doubling the NIH budget between 1998 and 2003. Since then, however, funding for the agency has not kept up with inflation. In fact, the NIH funds fewer than one out of five biomedical research grant applications, meaning that top-tier research is not being funded, Carey said. As a result, some of the best medical and scientific ideas are being left unexplored, and our most talented and creative scientists and our scientific leaders of the future are receiving a message of indifference.

Carey urged Congress to support a 6.7 percent increase for the NIH in each of the next three fiscal years. These increases would get the NIH back on track by restoring losses due to inflation in recent years. She also stressed the importance of NIH-funded training programs for the next generation of scientists and said NIH funds are essential to improving science education at all levels. The NIH also funds programs that provide important opportunities for minority students to become more deeply involved in scientific research.


'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
27-Mar-2007


Page: 1

Related biology news :

1. Contributing membership in the biomarkers consortium surges to 30 companies and nonprofits
2. AAAS urges US President to sign Embryonic Stem Cell Act
3. Virginia study urges early emphasis on science
4. NIH panel urges more informed approach to multivitamin/mineral use for chronic disease prevention
5. New journal article urges use of animal serum-free media for growing live cells
6. US Surgeon General urges Americans to know their family health history
7. To stem disease, keep cats indoors, stop feeding strays, scientist urges
8. AAAS CEO Alan I. Leshner urges US to continue collecting job data on women workers
9. Study urges caution in contaminant source tracking
10. The CF Foundation urges all states to include newborn screening for cystic fibrosis in test panels
11. New study warns limited carbon market puts 20 percent of tropical forest at risk

Post Your Comments:
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: